Advertisement

News from the European Society of Cardiology Congress — Physician’s First Watch

Medical News |
September 2, 2014

News from the European Society of Cardiology Congress

By the NEJM Journal Watch Editors

This weekend, CardioExchange has been reporting news from the European Society of Cardiology Congress in Barcelona, Spain. Here are some highlights:

  • Odyssey Long Term: In high risk patients, the PCSK9 inhibitor alirocumab was associated with a lower rate of cardiac death, myocardial infarction, and unstable angina requiring hospitalization (1.4% vs. 3% in the placebo group). But the results are a post-hoc analysis of a trial neither designed nor powered to study outcomes, so should be considered preliminary and speculative at best.

  • CvLPRIT: This open-label, randomized study comparing treatment of the infarct-related artery only with complete revascularization in 296 acute MI patients. At 12 months, there was a large, statistically significant reduction in the incidence of major adverse cardiac events in the complete revascularization group.

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement